DPAM
VRTX icon

Degroof Petercam Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Degroof Petercam Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.38M Hold
5,700
– – 0.03% 305
2023
Q4 		$2.32M Buy
+5,700
New +$2.11M 0.03% 310

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Degroof Petercam Asset Management's VRTX Position: Q1 2024 in Review

Degroof Petercam Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2024 at 5,700 shares worth $2.38M. The position accounts for 0.03% of the portfolio, ranked #305.

Degroof Petercam Asset Management first reported a position in VRTX in Q4 2023 and has held it in 2 quarters since. 1,494 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Degroof Petercam Asset Management held 5,700 shares of Vertex Pharmaceuticals worth $2.38M as of Q1 2024.
  • Degroof Petercam Asset Management left its Vertex Pharmaceuticals share count unchanged in Q1 2024.
  • Vertex Pharmaceuticals made up 0.03% of Degroof Petercam Asset Management's portfolio in Q1 2024, its #305 holding.
  • Degroof Petercam Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • 1,494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Degroof Petercam Asset Management's 13F filing for Q1 2024, filed 13 May 2024.